|
|
Betulinol Derivatives for Drug Resistant HIV
Aug 5, 2005, 19:01, Reviewed by: Dr.
|
|
Although these results appear to suggest a new composition for inhibiting the HIV virus that causes AIDS, additional pre-clinical studies are needed to determine the potential of this new derivative.
|
By Marc Pharmaceuticals, Inc.,
Preliminary experimental data from cellular tests conducted by university scientists working under a research grant sponsored by Marc Pharmaceuticals, Inc. (OTC:MPMA) (OTC:MPMAW) (OTC:MPMAZ) has demonstrated that a betulinol derivative inhibits HIV-1 replication by more than 90 percent with no evidence of detrimental changes to cell viability. These encouraging early stage results pave the way for further pre-clinical studies in drug resistant strains of HIV.
Betulinol is a naturally occurring compound that is isolated from the outer layer of the bark of the white birch tree. Betulinol derivatives are formed by replacing a specific atom or group of atoms within a betulinol molecule.
Although these results appear to suggest a new composition for inhibiting the HIV virus that causes AIDS, additional pre-clinical studies are needed to determine the potential of this new derivative. These early stage test results have not been proven in clinical trials and Marc Pharmaceuticals cannot predict whether this derivative will be useful for treating HIV infection or AIDS. 
- Marc Pharmaceuticals
www.marcpharmaceuticals.com
About Marc Pharmaceuticals:
Marc Pharmaceuticals is committed to identifying, developing and bringing to market, medicines and therapies that will elevate our quality of life and alleviate the suffering associated with debilitating and life threatening diseases. For more information, refer to the company Web site: www.marcpharmaceuticals.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
Statements in this release may relate to future events or Marc's future performance. Such statements are forward-looking statements that are subject to risks and uncertainties. Investors are cautioned that such forward-looking statements are subject to inherent risks that actual results may differ materially from such forward looking statements. Risks and uncertainties include but are not limited to, (a) Marc's products many not be proven to be safe or effective, (b) the FDA may not approve clinical trials for Marc's products, (c) Marc may depend substantially upon the efforts of contracting parties who may not perform adequately, (d) Marc's patent rights may not be sufficient to protect its products, (d) Marc may never earn a profit from its products, (e) Marc may not be able to raise the necessary funds that are needed for the continued research and development of its products, (f) Marc's licenses require substantial performance on its part to remain effective, including the payment of substantial sums, if Marc loses a license, it will lost the right to develop and market the drug which it covers, and (g) other groups may have developed similar inventions to those of Marc, and therefore Marc may be at a competitive disadvantage.
Contact Marc Pharmaceuticals
Robert M. Cohen,
203-352-8817
[email protected]
or
Michael A. Burns & Associates Virginia Stuart,
214-521-8596 [email protected]
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
